Gene · 2175
Papers3,803
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,881 to 1,900 of 3,803
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| The HSP90 inhibitor Onalespib exerts synergistic anti-cancer effects when combined with radiotherapy: an in vitro and in vivo approach. | Sci Rep | 2020 | 32246062 | PubTator, text mining | PubMed |
| Exome sequencing of familial high-grade serous ovarian carcinoma reveals heterogeneity for rare candidate susceptibility genes. | Nat Commun | 2020 | 32242007 | PubTator, text mining | PubMed |
| Exploring the Role of Mutations in Fanconi Anemia Genes in Hereditary Cancer Patients. | Cancers (Basel) | 2020 | 32235514 | PubTator, text mining | PubMed |
| Early Triple Negative Breast Cancer: Conventional Treatment and Emerging Therapeutic Landscapes. | Cancers (Basel) | 2020 | 32235297 | PubTator, text mining | PubMed |
| Honing in on PARPi Response in Prostate Cancer: from HR Pathway to Gene-by-Gene Granularity. | Clin Cancer Res | 2020 | 32234758 | PubTator, text mining | PubMed |
| Identification of a transcriptomic signature of food-relevant genotoxins in human HepaRG hepatocarcinoma cells. | Food Chem Toxicol | 2020 | 32234424 | PubTator, text mining | PubMed |
| Gingival Bleeding in a Child with Fanconi Anemia: A Case Report and Literature Review. | Case Rep Dent | 2020 | 32231808 | PubTator, text mining | PubMed |
| Effective Multi-lineage Engraftment in a Mouse Model of Fanconi Anemia Using Non-genotoxic Antibody-Based Conditioning. | Mol Ther Methods Clin Dev | 2020 | 32226796 | PubTator, text mining | PubMed |
| Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma. | J Immunother Cancer | 2020 | 32221016 | PubTator, text mining | PubMed |
| Pharmacological ascorbate induces 'BRCAness' and enhances the effects of Poly(ADP-Ribose) polymerase inhibitors against BRCA1/2 wild-type ovarian cancer. | Oncol Lett | 2020 | 32218813 | PubTator, text mining | PubMed |
| Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond. | Drugs R D | 2020 | 32215876 | PubTator, text mining | PubMed |
| Breast Cancer: A Molecularly Heterogenous Disease Needing Subtype-Specific Treatments. | Med Sci (Basel) | 2020 | 32210163 | PubTator, text mining | PubMed |
| Mesothelioma developing in carriers of inherited genetic mutations. | Transl Lung Cancer Res | 2020 | 32206572 | PubTator, text mining | PubMed |
| Corrigendum to "FANCA knockout in human embryonic stem cells causes a severe growth disadvantage" [Stem Cell Res.13/2 (2014) 240-50]. | Stem Cell Res | 2020 | 32199280 | PubTator, text mining | PubMed |
| Allele-specific genome targeting in the development of precision medicine. | Theranostics | 2020 | 32194858 | PubTator, text mining | PubMed |
| Inactivation of the Prolyl Isomerase Pin1 Sensitizes BRCA1-Proficient Breast Cancer to PARP Inhibition. | Cancer Res | 2020 | 32193285 | PubTator, text mining | PubMed |
| Fanconi anemia pathway as a prospective target for cancer intervention. | Cell Biosci | 2020 | 32190289 | PubTator, text mining | PubMed |
| Therapeutic targeting of the DNA damage response in prostate cancer. | Curr Opin Oncol | 2020 | 32168038 | PubTator, text mining | PubMed |
| Monoubiquitination by the human Fanconi anemia core complex clamps FANCI:FANCD2 on DNA in filamentous arrays. | Elife | 2020 | 32167469 | PubTator, text mining | PubMed |
How I curate: applying American Society of Hematology-Clinical Genome Resource Myeloid Malignancy Variant Curation Expert Panel rules for RUNX1 variant curation for germline predisposition to myeloid malignancies. | Haematologica | 2020 | 32165484 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/2175/papers?page=95